echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Phase 3 study of suofantinib in the treatment of advanced pancreatic neuroendocrine tumor

    Phase 3 study of suofantinib in the treatment of advanced pancreatic neuroendocrine tumor

    • Last Update: 2020-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 20, Hehuang pharmaceutical announced that the mid-term analysis of the phase III sanet-p study on advanced pancreatic neuroendocrine tumors by suvantinib reached the main end point, and the study will be terminated in advance Sanet-p is a phase III clinical trial in China The enrolled population is low-grade or middle-grade advanced pancreatic neuroendocrine tumor patients who have not been effectively treated at present In this study, patients were randomly treated with sufentanil 300mg or placebo once a day in a 2:1 ratio, 28 days as a treatment cycle The primary end point was progression free survival (PFS) The secondary end points included objective response rate (ORR), disease control rate (DCR), time to remission (TTR), duration of remission (DOR), total survival (OS), safety and tolerance Sufatinib is a new oral tyrosine kinase inhibitor independently developed by Hehuang pharmaceutical, which has dual activities of anti angiogenesis and immune regulation Sufentanil can block tumor angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), inhibit colony stimulating factor-1 receptor (CSF-1R), and promote immune response to tumor cells by regulating tumor related macrophages In November 2019, FDA awarded sofantini orphan drug qualification for treatment of pancreatic neuroendocrine tumor In the same month, the State Food and Drug Administration accepted the listing application (NDA) of sofantini for the treatment of non pancreatic neuroendocrine tumors, which was included in the priority review in December 2019 Neuroendocrine tumors originate from cells that interact with the nervous system or glands that produce hormones Neuroendocrine tumors can originate in many parts of the body, most commonly in the digestive tract or lungs, and can be benign or malignant tumors According to the origin, neuroendocrine tumors are usually divided into pancreatic neuroendocrine tumors and non pancreatic neuroendocrine tumors Approved targeted therapies include sunitinib malate and everolimus for the treatment of pancreatic neuroendocrine tumors or highly differentiated non functional gastrointestinal or pulmonary neuroendocrine tumors.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.